Navigation Links
Oracle Buys Relsys
Date:3/23/2009

Adds Advanced Drug Safety and Risk Management Applications to Extend Oracle's Leadership in Health Sciences

REDWOOD SHORES, Calif., March 23 /PRNewswire-FirstCall/ --

News Facts

  • Oracle today announced that it has agreed to acquire Relsys International, Inc. ("Relsys"), a leading provider of drug safety and risk management solutions with advanced analytics for the health sciences industry.
  • Relsys' best-in-class solutions support adverse event reporting, risk management, and data analysis for pharmaceutical, biotechnology, contract research organizations and medical device companies worldwide.
  • The combination of Oracle and Relsys is expected to deliver the only suite of software applications that supports end-to-end drug safety processes across clinical development, post-market surveillance and patient care, and is expected to extend Oracle's leadership in providing drug safety applications to the health sciences industry.
  • The addition of Relsys will bring significant domain knowledge and experience as part of Oracle's Health Sciences Global Business Unit, and is consistent with Oracle's strategy to provide mission-critical applications for key industries.
  • The transaction is subject to customary closing conditions and is expected to close in the first half of calendar year 2009.
  • Until the deal closes, each company will continue to operate independently.
  • Financial details of the transaction were not disclosed.

Supporting Quotes

  • "The health sciences industry is increasing investments in software that provide greater transparency into drug safety and help improve the overall safety of therapies," said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. "With the addition of Relsys, Oracle is uniquely positioned to help our customers improve drug safety by delivering a comprehensive software solution that enables our vision of integrated safety and risk management supported by advanced analytics."
  • "Identifying safety issues earlier in the development process can significantly reduce the costs and risks associated with bringing drugs and devices to market," said Dave Bajaj, President & CEO, Relsys. "Industry leaders trust Relsys' solutions to help them capture these benefits. We look forward to joining Oracle and helping provide the health sciences industry with the most complete, open and integrated suite of enterprise software."

Supporting Resources

About Oracle

Oracle (Nasdaq: ORCL) is the world's largest business software company. For more information about Oracle, please visit our Web site at http://www.oracle.com/.

Trademarks

Oracle is a registered trademark of Oracle Corporation and/or its affiliates. Other names may be trademarks of their respective owners.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020718/ORCLLOGO)


'/>"/>
SOURCE Oracle
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. TCS, Oracle and DrugLogic Prescribe Safety in a Capsule(TM)
2. Oracle Helps Mayo Clinic Improve Information Management
3. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
4. Oracle Introduces Remote Data Capture Onsite 4.5.3 With Extensive New Functionality for Investigative Site Personnel
5. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
6. Oracle Healthcare Acquisition Corp. Changes Record Date and Date of Special Meeting to Consider and Vote on Dissolution and Plan of Liquidation
7. Oracle Healthcare Acquisition Corp. Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation
8. MedTrust Online Collaborates With Oracle and Dell to Provide Oncologists With the Next Generation Tool for Personalized Care Delivery
9. Vgo Software First to Convert Oracle Forms to Oracle ADF v11
10. Sermes CRO Deploys Oracle(R) Clinical Applications to Support Growth
11. Bruce Palsulich Joins Relsys International as Chief Innovation & Strategy Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... PHILADELPHIA , Oct. 2, 2017 Halo Labs announces ... particle analysis system called the HORIZON at MIBio 2017 in ... analyzes subvisible and visible particulate matter in biopharmaceutical samples with unprecedented ... use of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: